Vicinitas Therapeutics Inc

Alumis provides precision medicines. They transform the lives of patients with autoimmune diseases. They bring a proven track record in precision drug development of groundbreaking therapies. They rewrite the autoimmune treatment playbook with a unique precision analytics platform to advancing their understanding of immunologic diseases. They build a pipeline of therapeutics based on genetically validated targets for application in the treatment of multiple autoimmune disease indications.

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information

Switch Therapeutics Inc, located in South San Francisco, is an emerging biotechnology company focused on pioneering innovative RNA interference (RNAi) medicines aimed at treating a range of central nervous system (CNS) diseases. Utilizing their proprietary Conditionally Activated siRNA (CASi) platform, they are developing biomarker-gated genetic therapies that enhance targeting and delivery, promising to address significant unmet medical needs in the CNS field. The CASi platform uniquely integrates properties of single and double-stranded RNA, facilitating efficient self-delivery and durable knockdown of targets within specific cell types. By enabling selective activation and expanding therapeutic windows for various diseases, Switch Therapeutics is positioned to revolutionize treatment options for patients facing debilitating CNS conditions. Generated from the website